Katie Keith

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification for pharmacies and clinicians and risk acknowledgment forms, are unlawful and must be reviewed. The lawsuit was filed by abortion providers in Kansas, Montana, and Virginia, with a similar case in Hawaii also finding the restrictions arbitrary.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification requirements for prescribers and pharmacies, were not sufficiently justified. The decision follows a lawsuit by abortion providers in Kansas, Montana, and Virginia, who argued the restrictions were excessive and inconsistent with legal requirements.

A federal judge ruled that the U.S. Food and Drug Administration’s 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful and require review. The restrictions, challenged by abortion providers in Kansas, Montana, and Virginia, include mandatory certification for pharmacies and clinicians and risk acknowledgment forms, which plaintiffs argue are excessive and medically unnecessary.

The Department of Justice and Ohio Attorney General proposed an antitrust settlement with OhioHealth, requiring the nonprofit hospital system to stop contracting practices that allegedly hindered insurers from offering cheaper policies. The swift resolution, announced four months after the lawsuit, is expected to prompt other hospitals to review their contracts.

The Trump administration finalized ACA changes allowing plans with higher out-of-pocket costs and no set provider networks, aiming to expand consumer choice but potentially reducing enrollment by up to 2 million next year. Experts warn these changes could erode ACA safeguards and worsen healthcare affordability challenges.